Breakthrough T1D shares the latest research at ISPAD
At the 2024 International Society for Pediatric and Adolescent Diabetes (ISPAD) Conference in Lisbon, Portugal, the world’s leading diabetes researchers,…
Breakthrough T1D and the Nobel Prizes: Connected!
It’s early October, which means the Nobel Prizes are being awarded in several categories. These prestigious awards recognize outstanding contributions…
Powering research breakthroughs
We invest in the most promising research to turn ideas into life-changing therapies and lead the way to cures.
What Drug Will Be the Next Tzield?
In 2023 alone, there have been several important papers published on disease-modifying therapies (DMT) for type 1 diabetes. This blog…
FDA-Approved Immune Therapy Shows Benefit in Newly Diagnosed
In a Breakthrough T1D-funded clinical trial and published in the New England Journal of Medicine, baricitinib preserved beta cell function…
Results Are Out: Tzield Benefits Newly Diagnosed Individuals
A new study published in the New England Journal of Medicine shows Tzield can preserve beta cell health in certain…
Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
Breakthrough T1D & NIH Workshop at the Intersection of Immunology and Bioengineering
Breakthrough T1D and NIH bring together top scientists and engineers to strategize on how to allow implanted beta cells to…
Teplizumab (the Therapy that Delays T1D By Nearly 3 Years) Isn’t Approved…Yet
The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning…
FDA Advisory Committee Recommends that Teplizumab Receives Approval
An FDA Advisory Committee weighed the evidence, and the results were positive: They recommended that the FDA approve teplizumab for…
